top of page

Our portfolio of investment opportunities

With thorough due diligence process and careful experimental verification, we effectively de-risk our early investment opportunities, ensuring optimal value for our investors

For investors

Type of Investments

​Pre-seed funding:

  • Direct investment in pre-company stage biotech projects

  • Participation in acceleration programs through investments in dedicated and regulated funds or selected projects

​Seed funding:

  • Investment in NewCos/start-ups established based on incubated projects or positively concluded due diligence processes

  • Typically ranging from €1.5 to €4 million, often supplemented with non-dilutive grant financing

Series A funding of Start-ups:

  • Investment in pre-clinical development stage companies following pre-seed and/or seed financing

Current Opportunities

  • Selected projects from Danube Labs and the DanubeNeuro dedicated fund

  • 2 NewCos to be incorporated in Q2-Q3 2024, evolving from the DanubeLabs acceleration program

  • Portfolio includes Eveliqure Biotechnologies, Calyxha Biotechnologies, Algonist Biotechnologies

Get in touch

We're here to collaborate and innovate -

contact us to start the conversation

+43 (0)1 9092208

For Partnering

We actively seek partners for the next phase of commercialization of our drug development projects, through co-development or licensing. 

Therapeutic fields

  • Cardiovascular and metabolic diseases

  • Lung fibrosis

  • Cancer immunotherapy

  • Anti-infectives

Therapeutic modalities

  • Small molecules

  • RNA therapeutics

  • Biologics (antibodies, proteins, peptides)

bottom of page